0001209191-21-066884.txt : 20211124
0001209191-21-066884.hdr.sgml : 20211124
20211124195914
ACCESSION NUMBER: 0001209191-21-066884
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211122
FILED AS OF DATE: 20211124
DATE AS OF CHANGE: 20211124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Detheux Michel
CENTRAL INDEX KEY: 0001816196
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211448825
MAIL ADDRESS:
STREET 1: C/O ITEOS THERAPEUTICS, INC.
STREET 2: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-22
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001816196
Detheux Michel
139 MAIN STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Executive Officer
Common Stock
2021-11-22
4
M
0
16263
12.45
A
92700
D
Common Stock
2021-11-23
4
S
0
14500
36.08
D
78200
D
Stock Option (right to buy)
12.45
2021-11-22
4
M
0
16263
0.00
D
2015-11-13
2021-12-16
Common Stock
16263
0
D
This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.48 to $36.48, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The option is fully vested.
/s/ Adi Osovsky, as Attorney-in-Fact
2021-11-24